Metoprolol Succinate Tablet, Extended Release
Product Images NDC 70518-3164

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Metoprolol Succinate (NDC 70518-3164). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Metoprolol Succinate 50mg 70518 3164 01

Label for metoprolol succinate extended-release 50 mg tablets, carton or bottle label indicating quantity of 90 tablets. The label includes the NDC number 70518-3164-01, manufacturer Zydus Pharm in New Jersey, and repackager RemedyRepack Inc. Usage directions refer to package insert. Storage conditions are noted as 20-25°C with permitted excursions. The label also displays a QR code and cautions to keep medication out of reach of children.*

FDA Label Image

Remedy_label (Remedy Label)

Metoprolol Succinate 50 mg extended-release tablets, quantity 30, in a repackaged container by RemedyRepack Inc. Label includes NDC 70518-3164-00 and notes original manufacturer Zydus Pharm, Pennington, NJ. Directions advise storage at 20-25°C with permitted excursions and to see the package insert for use instructions.*

FDA Label Image

Figure (Fe222a69 B261 4e41 83ab Af76ee17812d 01)

Chemical structure diagram of metoprolol succinate, showing the molecular arrangement of its components.*

FDA Label Image

Figure (Fe222a69 B261 4e41 83ab Af76ee17812d 02)

A three-panel forest plot chart titled 'Results for Subgroups in MERIT-HF' showing relative risk and 95% confidence intervals for metoprolol succinate compared to placebo across different patient subgroups. The panels display outcomes for Total Mortality, Total Mortality or All-Cause Hospitalization, and Total Mortality or Hospitalization for Heart Failure, with subgroup categories listed on the left and risk favoring either metoprolol succinate or placebo on the x-axis.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.